Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering
June 06, 2022 08:30 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
Aquestive Therapeutics Announces CEO Transition
May 17, 2022 16:01 ET
|
Aquestive Therapeutics, Inc.
Daniel Barber, current Chief Operating Officer of Aquestive, appointed as President and Chief Executive Officer and member of Board of DirectorsKeith Kendall, President and Chief Executive Officer and...
Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
May 10, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care...
Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 03, 2022 17:41 ET
|
Aquestive Therapeutics, Inc.
FDA continues to consider orphan drug exclusivity issues regarding Libervant's NDACommon stock purchase agreement secured for up to $40 millionPart 3 of EPIPHAST trial for AQST-109 commenced in April...
Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET
April 18, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., April 18, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care...
Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital
April 13, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
Provides Access to Additional Capital to Support Growth WARREN, N.J., April 13, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to...
Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
April 12, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development Rapid absorption with a median time to peak concentration (Tmax) of 15 minutes confirmed in a...
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
March 17, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care...
Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance
March 08, 2022 16:56 ET
|
Aquestive Therapeutics, Inc.
Continues to interact with FDA regarding orphan drug review of the NDA for Libervant™ (diazepam) Buccal FilmReports start of Part 2 of EPIPHAST crossover study for AQST-109 epinephrine oral film after...
Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China
March 03, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current...